(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 March 2007 (01.03.2007)

PCT

(10) International Publication Number
WO 2007/022980 A1

(51) International Patent Classification:
A61K 31/403 (2006.01)

(21) International Application Number:
PCT/EP2006/008314

(22) International Filing Date: 21 August 2006 (21.08.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0517193.9 22 August 2005 (22.08.2005) GB

(71) Applicant *(for all designated States except US)*: **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HAMPRECHT, Dieter** [DE/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37135 Verona (IT). **HEIDBREDER, Christian** [BE/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37135 Verona (IT). **MELOTTO, Sergio** [IT/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37135 Verona (IT). **MICHELI, Fabrizio** [IT/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37135 Verona (IT). **YAMADA, Tadataka** [JP/US]; GlaxoSmithKline, One Franklin Plaza, 200n 16th Street, Philadelphia, Pennsylvania 19102-1225 (US).

(74) Agent: **GIDDINGS, Peter, John**; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF AZABICYCLO HEXANE DERIVATIVES



(I)

(57) Abstract: The present invention provides a new use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate salt thereof, wherein: G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R_1 is independently selected from a group consisting of: halogen, hydroxyl, cyano, C1-4alkyl, haloC1-4alkyl, C_{1-4} alkoxy, haloC_{1-4}alkoxy, C_{1-4}alkanoyl; or corresponds to a group R_5; R_2 is hydrogen or C_{1-4} alkyl; R_3 I s C_{1-4}alkyl; R_4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C_{1-4}alkyl, haloC_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}alkanoyl; R_5 is a moiety selected from the group consisting of: isoxazolyl, -CH_2-N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, C_{1-4}alkyl, haloC_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}alkanoyl; and when R_1 is chlorine and p is 1, such R_1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R_1 corresponds to R_5, p is 1; in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the manufacture of a medicament for the treatment of premature ejaculation.

WO 2007/022980 A1